SCHEMBL2086606

SCHEMBL2086606

COc1ccc(/N=C(/NC#N)Oc2ccccc2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.51
HPGD P15428 2/20 0.41
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 5/20 0.38
IMPDH2 P12268 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
PKM P14618 1/20 0.37
CYP1B1 Q16678 1/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CREBBP Q92793 1/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2086607 1.00 KMT2A (0.51) KMT2AHPGDNPC1RAB9AMAPT
SCHEMBL2086872 0.87 KMT2A (0.56) KMT2AHPGDRAB9AMAPTALDH1A1
SCHEMBL2086875 0.87 KMT2A (0.56) KMT2AHPGDRAB9AMAPTALDH1A1
SCHEMBL4037230 0.80 KMT2A (0.72) KMT2AHPGDNPC1RAB9AMAPT
SCHEMBL2088564 0.79 KMT2A (0.59) KMT2AHPGDMAPTMEN1ALDH1A1
SCHEMBL2088642 0.79 KMT2A (0.62) KMT2AHPGDNPC1RAB9AMEN1
SCHEMBL2088566 0.79 KMT2A (0.59) KMT2AHPGDMAPTMEN1ALDH1A1
SCHEMBL2088643 0.79 KMT2A (0.62) KMT2AHPGDNPC1RAB9AMEN1
SCHEMBL4781017 0.76 KMT2A (0.58) KMT2AMEN1IMPDH2
SCHEMBL4781020 0.76 KMT2A (0.58) KMT2AMEN1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
EP-1562589-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-17 EP disclosed
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-28 US disclosed
WO-2004046120-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 KMT2A 912/4885HPGD 1347/4885NPC1 2770/4885
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K5 KMT2A 912/4885HPGD 1347/4885NPC1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.